Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma with Sorafenib in a Reference Center in Mexico

Axel Costilla-Montero, Benjamín Guadarrama-Benítez, Marco A. Aragón-Castro, Omar Morales-Ordaz, Rubén Gutiérrez-Rosales, Claudia Carrillo-Ponce, Marcela Janka-Zires, Luis Gabriel Vázquez-Lavista

.
Departament of Urology Centro Médico ISSEMYM Toluca, Toluca, México.

DOI: 10.4236/ss.2011.26077                

Abstract

Background: neo - adjuvant therapy is usually indicated in locally advanced tumors, the aim is to decrease the tumoral burden and enhance overall survival. Renal cell carcinoma is a chemo and radio resistant neoplasm and this type of approach is not as effective as in other solid tumors. On the other hand immunotherapy is indicated in metastatic disease, demonstrating a better overall survival. Sorafenib is an antiangiogenic drug approved for locally advanced or metastatic RCC. We postulated that it can be used in a neoadjuvant way to decrease the vascularization of selected tumors. Report of the case: 57 years old male referred to our service with a right renal mass and metastatic disease to lumbar spine and suprarenal gland. He was treated with three months of sorafenib previous to the surgery. Results: The patient went into surgery three months after initiating the antiangiogenic drug, during the surgery we found less neo-formance vessels; the dissection was subjectively easier, due to peri-renal edema. The pathologic analysis of the specimen was renal cell carcinoma. Interestingly, 40% of central ischemic (coagulative) necrosis was found. Conclusion: There are no neoadjuvant drugs accepted for the treatment of renal cell carcinoma; using an antiagiogenic drug to decrease the vascular burden characteristic of this type of tumors could be a viable option in selected cases. We used a lower dose of the drug with an acceptable safety profile.

Keywords

Renal Cell Carcinoma, Antiagiogenic Drugs, Neoadyvant Therapy, Sorafenib

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. Jemal, T. Murray and E. Ward, “Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 1, 2005, pp. 10-30. doi:10.3322/canjclin.55.1.10
[2]	Instituto Nacionall de Oncologia, “Manual de Oncologia Médica,” Procedimentos Medico Quirurgicos, 2a Edición, McGraw Hill, Boston, 2002.
[3]	L. M. Hock, J. Lynch and K. C. Balaji, “Increasing Incidences of all Stages of Kidney Cancer in the United States: An Analysis of Surveillance, Epidemiology and End Results Program Data,” Journal of Urology, Vol. 167, No. 1, 2002, pp. 57-60. doi:10.1016/S0022-5347(05)65382-7
[4]	S. Ramsay and M. Aithkinson, “Treatment of Renal Cell Carcinoma: Are We beyond the Cytokine Era?” Nature Clinical Practice Urology, Vol. 3, No. 9, 2006, pp. 478-484. doi:10.1038/ncpuro0581
[5]	E. Soto-Vega, C. Arroyo, Y. Richaud-Patin, M. García-Carrasco, L. G. Vázquez-Lavista and L. Llorente “P- Glycoprotein Activity in Renal Clear Cell Carcinoma,” Urologic Oncology, Vol. 27, No. 4, 2009, pp. 363-366. doi:10.1016/j.urolonc.2008.01.011
[6]	R. J. Motzer, T. E. Hutson, P. Tomczak, et al., “Sunitinib versus Interferon Alpha in Metastatci Renal Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, No. 2, 2007, pp. 115-124. doi:10.1056/NEJMoa065044
[7]	B. Escudier, “Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, No. 2, 2007, pp. 125-134. doi:10.1056/NEJMoa060655
[8]	J. C. Young, L. Haworth, R. M. Sherry, et al., “A Randomized Trial of Bevacizumav an Antivascular Endothelial Growth Factor Antibody for Metastatic Renal Cell Cancer,” The New England Journal of Medicine, Vol. 349, No. 5, 2003, pp. 427-434. doi:10.1056/NEJMoa021491
[9]	C. Wood, et al., “Neoadjuvant (Presurgical) Therapy for Renal Cell Carcinoma: A New Treatment Paradigm for Locally Advanced and Metastatic Disease,” Cancer, Vol. 115, No. S10, 2009, pp. 2355-2360. doi:10.1002/cncr.24240
[10]	National Comprehensive Cancer Network, “Clinical Practice Guidelines in OncologyTM,” Kidney Cancer, V2, 2010. www.nccn.org
[11]	F. Di siverio, A. Sciarra, U. Parente, A. Andrea, M. Von Heland, V. Panebianco and R. Passariello, “Neoadjuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical Nephrectomy,” Urologia Internationalis, Vol. 80, No. 4, 2008, pp. 451-453.
[12]	L. C. Harshman, R. J. Yu, G. I. Allen, S. Srinvas, H. S. Gill and B. I. Chung, “Surgical Outcomes and Complications Associated with Presurgical Tyrosine Kinase Inhibition for Advanced Renal Cell Carcinoma (RCC),” Urologic Oncology, 24 February 2011.
[13]	G. Mickisch, J. Carballido, S. Hellsten, H. Schulze, H. Mensink and European Association of Urology, “Guidelines on Renal Cell Cancer,” European Urology, Vol. 40, No. 3, 2001, pp. 252-255. doi:10.1159/000049783